Blood cells may offer telltale clues in cancer diagnosis

October 12, 2012
Devin Koestler is a biostatistician whose research is focused on the development and application of statistical methods for analyzing genomic data. Credit: Eli Burakian

Postdoctoral Research Fellow Devin Koestler is a biostatistician in the Geisel School of Medicine at Dartmouth. He develops and applies statistical methods to large volumes of data, seeking new approaches for understanding disease, cancer in particular. Koestler and his colleagues are investigating the potential use of white blood cell variation as a diagnostic, predictive, and research tool in the study of non-blood cancers.

"There is promise here for a new diagnostic tool," says Koestler. "What we show here is not ready for immediate clinical utility, but I think it is on the right path."

Koestler is working in the Quantitative Biomedical Sciences program with Professors Margaret Karagas and Jason Moore. His focus is the development of computational and statistical tools for investigating the process of DNA methylation.

In methylation, a molecule known as a (chemically CH3—three and one carbon) attaches itself to the DNA. When this occurs, the DNA function can change dramatically. An example might be the methyl group blocking the expression of a tumor-suppressing gene.

Koestler is the first author on a paper with Karagas and a host of colleagues from Dartmouth, Brown University, Oregon State University, the University of Minnesota and the University of California. Its subject is methylation in leukocytes () and their association with in tissues and organs other than blood, such as bladder or .

"When we have an illness or a disease, that does something to our immune system," Koestler explains. "It responds by providing whatever cells are necessary to combat that threat. In the blood, the leukocytes supply that immune response."

Methylation has been studied in biopsied cells from cancer patients, in comparison to cells of cancer-free individuals. "Those studies have compellingly shown there are very striking differences in methylation patterns between cancer and cancer-free subjects," Koestler says. "This brought us to also look at patterns of methylation in blood."

The new studies, in which Koestler took part, showed differences in methylation patterns in the leukocytes of versus cancer-free individuals. There are different types of leukocytes, referred to as subsets, each of which exhibits its own signature methylation pattern. The proportions of these identifiable subsets shift, depending on the kind of disease they may be combating.

Using data from studies of ovarian, bladder, and head and neck cancers, the researchers demonstrated statistically significant correlations between the specific cancers and the methylation signatures that characterize leukocyte subsets.

"What made our study unique is that we had the methylation data on the individual leukocytes themselves, enabling us to connect the dots, and better understand the mechanisms underlying the results from previous studies."

Analyzing the relative proportions of the leukocyte types in the blood sample can help predict the onset of a particular cancer or identify and diagnose a cancer in progress. The alternative of sampling a patient's blood is far preferable to undergoing an invasive surgical biopsy.

The advantages of using methylation patterns to assess proportions of white blood cell subtypes in cancer research extend beyond the bedside to the lab bench. Archival blood samples frozen and stored at some time in the past can now be used as research material, whereas existing methods typically require fresh blood samples with intact cells to assess white blood cell subtypes.

Explore further: Technique spots disease using immune cell DNA

Related Stories

Technique spots disease using immune cell DNA

July 9, 2012
When a person is sick, there is a tell-tale sign in their blood: a different mix of the various types of immune cells called leukocytes. A group of scientists at several institutions including Brown University has discovered ...

DNA methylation level is marker of breast cancer risk

May 11, 2012
(HealthDay) -- Women with high levels of white blood cell (WBC) DNA methylation at the ATM loci have a significantly increased risk of breast cancer, regardless of family history or menopausal status, according a study published ...

Unique genetic marker may improve detection of recurrent ovarian cancer

December 7, 2011
Ovarian cancer is a major health concern for women and the identification of sensitive biomarkers for early detection and/or monitoring of disease recurrence is of high clinical relevance.

Recommended for you

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.